Verona Pharma Plc ADR (NASDAQ: VRNA) is 393.73% higher on its value in year-to-date trading and has touched a low of $18.51 and a high of $104.99 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VRNA stock was last observed hovering at around $104.67 in the last trading session, with the day’s gains setting it 0.1%.
Currently trading at $104.77, the stock is 9.30% and 24.12% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 10.54 million and changing 0.10% at the moment leaves the stock 79.56% off its SMA200. VRNA registered 125.60% gain for a year compared to 6-month gain of 131.79%. The firm has a 50-day simple moving average (SMA 50) of $83.7569 and a 200-day simple moving average (SMA200) of $57.97365.
The stock witnessed a 13.27% loss in the last 1 month and extending the period to 3 months gives it a 81.55%, and is 20.62% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 0.20% over the week and 2.82% over the month.
Verona Pharma Plc ADR (VRNA) has around 209 employees, a market worth around $8.92B and $118.55M in sales. Fwd P/E is 138.87. Profit margin for the company is -138.52%. Distance from 52-week low is 466.02% and -0.21% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.98%).
The EPS is expected to grow by 161.28% this year.
Verona Pharma Plc ADR (VRNA) Top Institutional Holders
321.0 institutions hold shares in Verona Pharma Plc ADR (VRNA), with institutional investors hold 101.54% of the company’s shares. The shares outstanding are 85.13M, and float is at 76.73M with Short Float at 9.39%. Institutions hold 90.98% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 7.63 million shares valued at $110.37 million. The investor’s holdings represent 1.1775% of the VRNA Shares outstanding. As of 2024-06-30, the second largest holder is MORGAN STANLEY with 0.86 million shares valued at $12.49 million to account for 1.0663 of the shares outstanding. The other top investors are NEA MANAGEMENT COMPANY, LLC which holds 5.58 million shares representing 0.8616% and valued at over $80.76 million, while DEEP TRACK CAPITAL, LP holds 0.6171 of the shares totaling 4.0 million with a market value of $57.84 million.
Verona Pharma Plc ADR (VRNA) Insider Activity
The most recent transaction is an insider sale by Fisher Andrew, the company’s General Counsel. SEC filings show that Fisher Andrew sold 80,000 shares of the company’s common stock on Jun 16 ’25 at a price of $11.53 per share for a total of $0.92 million. Following the sale, the insider now owns 0.36 million shares.
Verona Pharma Plc ADR disclosed in a document filed with the SEC on Jun 11 ’25 that Hahn Mark W (Chief Financial Officer) sold a total of 400,000 shares of the company’s common stock. The trade occurred on Jun 11 ’25 and was made at $11.40 per share for $4.56 million. Following the transaction, the insider now directly holds 12.28 million shares of the VRNA stock.
Still, SEC filings show that on Jun 11 ’25, ZACCARDELLI DAVID (President and CEO) disposed off 400,000 shares at an average price of $11.40 for $4.56 million. The insider now directly holds 13,190,168 shares of Verona Pharma Plc ADR (VRNA).
